Siegfried Holding AG, commonly referred to as Siegfried, is a prominent player in the pharmaceutical and chemical industry, headquartered in Switzerland (CH). Founded in 1873, the company has established a strong presence in Europe and North America, focusing on the development and manufacturing of active pharmaceutical ingredients (APIs) and finished dosage forms. Siegfried is renowned for its innovative solutions in contract development and manufacturing, catering to a diverse clientele in the pharmaceutical sector. The company’s commitment to quality and sustainability sets it apart, ensuring compliance with stringent regulatory standards. With a robust market position, Siegfried has achieved significant milestones, including strategic acquisitions that have expanded its capabilities and global reach. As a trusted partner in the pharmaceutical supply chain, Siegfried continues to drive advancements in drug development and production.
How does Siegfried Holding's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Siegfried Holding's score of 72 is higher than 82% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2024, Siegfried Holding AG reported total carbon emissions of approximately 59171000 kg CO2e for Scope 1, 12622000 kg CO2e for Scope 2, and 459700000 kg CO2e for Scope 3, resulting in a combined total of about 71793000 kg CO2e for Scope 1 and 2 emissions. This reflects a slight increase in Scope 1 emissions compared to 2023, where they were approximately 58411000 kg CO2e, while Scope 2 emissions decreased from 14617000 kg CO2e in 2023. Siegfried has set ambitious climate commitments, aiming for a 50% reduction in its Scope 1 and 2 emissions by 2030, based on 2020 revenue-adjusted figures. This target is part of a broader strategy to achieve net-zero greenhouse gas emissions across its value chain by 2050. Additionally, the company has committed to reducing its absolute Scope 1 and 2 emissions by 66.89% by 2033 from a 2020 baseline, and to cut Scope 3 emissions from specific activities by 32.5% by 2033 from a 2022 baseline. Siegfried's climate initiatives are aligned with the Science Based Targets initiative (SBTi), and they are committed to ensuring that 85% of their suppliers by emissions will have science-based targets by 2029. The company is actively working towards these goals, demonstrating a strong commitment to sustainability and climate action within the pharmaceutical sector.
Access structured emissions data, company-specific emission factors, and source documents
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 16,300,000 | - | - | - | - | - | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | - | - | - | - | - | - | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | - | - | - | - | 000,000,000 | 000,000,000 | 000,000,000 |
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Siegfried Holding has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.

Common questions about Siegfried Holding's sustainability data and climate commitments